当前位置: X-MOL 学术Cell Biol. Toxicol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Statins induce skeletal muscle atrophy via GGPP depletion-dependent myostatin overexpression in skeletal muscle and brown adipose tissue
Cell Biology and Toxicology ( IF 6.1 ) Pub Date : 2020-10-09 , DOI: 10.1007/s10565-020-09558-w
Lai Wang 1 , Zu-Guo Zheng 1 , Lingchang Meng 1 , Lijun Zhu 1 , Ping Li 1 , Jun Chen 1 , Hua Yang 1
Affiliation  

Myopathy is the major adverse effect of statins. However, the underlying mechanism of statin-induced skeletal muscle atrophy, one of statin-induced myopathy, remains to be elucidated. Myostatin is a negative regulator of skeletal muscle mass and functions. Whether myostatin is involved in statin-induced skeletal muscle atrophy remains unknown. In this study, we uncovered that simvastatin administration increased serum myostatin levels in mice. Inhibition of myostatin with follistatin, an antagonist of myostatin, improved simvastatin-induced skeletal muscle atrophy. Simvastatin induced myostatin expression not only in skeletal muscle but also in brown adipose tissue (BAT). Mechanistically, simvastatin inhibited the phosphorylation of forkhead box protein O1 (FOXO1) in C2C12 myotubes, promoting the nuclear translocation of FOXO1 and thereby stimulating the transcription of myostatin. In differentiated brown adipocytes, simvastatin promoted myostatin expression mainly by inhibiting the expression of interferon regulatory factor 4 (IRF4). Moreover, the stimulative effect of simvastatin on myostatin expression was blunted by geranylgeranyl diphosphate (GGPP) supplementation in both myotubes and brown adipocytes, suggesting that GGPP depletion was attributed to simvastatin-induced myostatin expression. Besides, the capacities of statins on stimulating myostatin expression were positively correlated with the lipophilicity of statins. Our findings provide new insights into statin-induced skeletal muscle atrophy.



中文翻译:

他汀类药物通过骨骼肌和棕色脂肪组织中 GGPP 耗竭依赖性肌生长抑制素过表达诱导骨骼肌萎缩

肌病是他汀类药物的主要不良反应。然而,他汀类药物引起的骨骼肌萎缩(他汀类药物引起的肌病之一)的潜在机制仍有待阐明。肌肉生长抑制素是骨骼肌质量和功能的负调节剂。肌肉生长抑制素是否与他汀类药物诱导的骨骼肌萎缩有关仍然未知。在这项研究中,我们发现辛伐他汀给药会增加小鼠的血清肌生长抑制素水平。用肌生长抑制素拮抗剂卵泡抑素抑制肌生长抑制素可改善辛伐他汀诱导的骨骼肌萎缩。辛伐他汀不仅在骨骼肌中而且在棕色脂肪组织 (BAT) 中诱导肌肉生长抑制素表达。从机制上讲,辛伐他汀抑制 C2C12 肌管中叉头盒蛋白 O1 (FOXO1) 的磷酸化,促进 FOXO1 的核转位,从而刺激肌肉生长抑制素的转录。在分化的棕色脂肪细胞中,辛伐他汀主要通过抑制干扰素调节因子 4 (IRF4) 的表达来促进肌肉生长抑制素的表达。此外,在肌管和棕色脂肪细胞中补充香叶基香叶基二磷酸 (GGPP) 会减弱辛伐他汀对肌肉生长抑制素表达的刺激作用,表明 GGPP 消耗归因于辛伐他汀诱导的肌肉生长抑制素表达。此外,他汀类药物刺激肌肉生长抑制素表达的能力与他汀类药物的亲脂性呈正相关。我们的发现为他汀类药物引起的骨骼肌萎缩提供了新的见解。辛伐他汀主要通过抑制干扰素调节因子4(IRF4)的表达来促进肌肉生长抑制素的表达。此外,在肌管和棕色脂肪细胞中补充香叶基香叶基二磷酸 (GGPP) 会减弱辛伐他汀对肌肉生长抑制素表达的刺激作用,表明 GGPP 消耗归因于辛伐他汀诱导的肌肉生长抑制素表达。此外,他汀类药物刺激肌肉生长抑制素表达的能力与他汀类药物的亲脂性呈正相关。我们的发现为他汀类药物引起的骨骼肌萎缩提供了新的见解。辛伐他汀主要通过抑制干扰素调节因子4(IRF4)的表达来促进肌肉生长抑制素的表达。此外,在肌管和棕色脂肪细胞中补充香叶基香叶基二磷酸 (GGPP) 会减弱辛伐他汀对肌肉生长抑制素表达的刺激作用,表明 GGPP 消耗归因于辛伐他汀诱导的肌肉生长抑制素表达。此外,他汀类药物刺激肌肉生长抑制素表达的能力与他汀类药物的亲脂性呈正相关。我们的发现为他汀类药物引起的骨骼肌萎缩提供了新的见解。表明 GGPP 耗竭归因于辛伐他汀诱导的肌生长抑制素表达。此外,他汀类药物刺激肌肉生长抑制素表达的能力与他汀类药物的亲脂性呈正相关。我们的发现为他汀类药物引起的骨骼肌萎缩提供了新的见解。表明 GGPP 耗竭归因于辛伐他汀诱导的肌生长抑制素表达。此外,他汀类药物刺激肌肉生长抑制素表达的能力与他汀类药物的亲脂性呈正相关。我们的发现为他汀类药物引起的骨骼肌萎缩提供了新的见解。

更新日期:2020-10-11
down
wechat
bug